AI Proteins Raises $41.5 Million Series A to Advance AI-Designed Miniprotein Therapeutics
AI Proteins, a Boston-based biotech company pioneering artificial-intelligence-driven design of de novo miniprotein therapeutics, has successfully closed a $41.5 million Series A financing round to advance its novel drug discovery platform and expand its therapeutic pipeline. The financing round, announced in late November 2025, underscores growing investor interest in the intersection of AI and next-generation biologics.
The Series A funding was led by Mission BioCapital and Santé Ventures, two venture investors focused on transformative life sciences and biotechnology opportunities. These lead investors were joined by participation from existing backers, including Lightchain Capital and Cobro Ventures, helping to bring substantial capital into a space where AI-enabled protein engineering is increasingly viewed as a strategic advantage in therapeutic discovery.
AI Proteins’ platform leverages advanced machine learning methods to create unique, fully designed protein structures from first principles, enabling precise control over biological function and pharmacology. This approach sets it apart from traditional biologics discovery methods, which often rely on modifying naturally occurring proteins or extensive iterative experimentation. The company’s proprietary technology aims to compress timelines and reduce costs associated with bringing novel protein therapeutics toward clinical development.
According to the financing announcement, the capital raised will support the continued development of AI Proteins’ internal pipeline of modular miniproteins, with applications spanning multiple therapeutic areas. The company has adopted a hub-and-spoke business model, designed to protect and scale its core AI platform while enabling specialized programs to operate with focused autonomy. This structure is intended to maximize innovation and value creation as each program advances toward clinical and regulatory milestones.
Founded with the mission to re-imagine protein therapeutics, AI Proteins combines high-throughput AI design with experimental validation to generate candidates that are optimized for specific therapeutic functions. By constructing proteins de novo, as opposed to repurposing existing biological molecules, the company seeks to unlock capabilities that could lead to treatments for diseases currently lacking effective therapies.
The participation of both established and specialist venture firms reflects broader investor confidence in technologies that harness AI for biological discovery. Mission BioCapital, known for backing platforms that fuse computational and experimental biology, brings strategic support for companies aiming to transform drug discovery. Likewise, Santé Ventures focuses on early-stage life sciences companies with differentiated technology platforms. Lightchain Capital and Cobro Ventures add capital and sector expertise, having supported emerging biotech companies across innovative fields.
Industry analysts note that a wave of investments into AI-centric biotech firms has accelerated in recent years as computational tools demonstrate real-world impact on R&D workflows. These tools have shown promise not only in identifying candidate molecules more efficiently, but also in reshaping entire discovery paradigms across oncology, immunology, and rare diseases. AI Proteins’ successful Series A round positions it among peers seeking to bring AI-designed biology into mainstream drug development.
The company’s strategy emphasizes both its internal discovery efforts and potential collaborations with larger biopharmaceutical partners. By building a modular platform that can generate a diverse array of proteins tailored for specific targets, AI Proteins hopes to establish a pipeline of assets that could enter IND-enabling studies and, ultimately, clinical trials.
The new funding is expected to accelerate hiring in AI research, computational biology, and wet lab experimentation, as well as to expand infrastructure needed to support more complex therapeutic programs. It also enhances AI Proteins’ ability to pursue strategic partnerships that could further validate its technology across therapeutic modalities and disease areas.
As the biotech sector increasingly embraces AI to address scientific bottlenecks, AI Proteins’ Series A financing reflects the confidence of investors in its technology and vision. The company now stands poised to advance its de novo miniprotein therapeutics with the resources needed to push toward next stages of development, contributing to a broader movement toward AI-enabled biological innovation.
